olivLaw · US equity research
IceCure Medical Ltd. ICCM
Surgical & Medical Instruments & Apparatus · SIC 3841 · Vertical: Surgical & Medical Instruments & Apparatus (SIC 3841)
IceCure Medical Ltd. is a medical device company based in Caesarea, Israel, focused on liquid nitrogen cryoablation systems that destroy tumors through a minimally invasive procedure. The company received FDA marketing authorization in October 2025 for ProSense in low-risk breast cancer in women aged 70 and above, yet its revenue remains small at about 3.379 mn USD in fiscal 2025 while its accumulated deficit exceeds 120.4 mn USD.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, IceCure Medical Ltd. (ICCM) stock was 0.79 USD (+2.59% on the day), with market capitalisation 57.8 m USD, P/E 3.3 on diluted EPS of 0.24 USD over the last 12 months, beta 0.44, 52-week range 0.77–21.90 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 18.3
- oversold (≤ 30)
- Bollinger (20, 2)
- 0.80 – 1.21
- below the lower band · %B -0.02 · band width 40.6%
- SMA 50 / 200
- 1.57 / 7.79
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.22 / -0.23
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −48.6% | −1.1% | −47.5 pp | — |
| 3 months | −75.4% | −0.5% | −74.9 pp | — |
| 6 months | −90.1% | +4.4% | −94.5 pp | — |
| Year to date | −95.7% | +12.3% | −108.0 pp | — |
| 1 year | −96.4% | +13.5% | −109.9 pp | −29.7% |
| 3 years | −96.5% | +76.4% | −172.9 pp | −20.7% |
| 5 years | −99.7% | +63.7% | −163.3 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 0 percentile of its own 5-quarter history (min 76.3, median 101.1, max 261.4; quarters with earnings only).
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.6 m | 3.9 m | 4.1 m | 3.1 m | 3.2 m | 3.3 m | 3.4 m |
| Revenue YoY | unavailable | +137.7% | +7.0% | −25.4% | +4.7% | +1.9% | +2.7% |
| Net income | -4.6 m | -3.7 m | -9.9 m | -17.0 m | -14.7 m | -15.3 m | -15.1 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | 0.33 | 0.22 | 0.35 | 0.46 | 0.32 | 0.30 | 0.24 |
| Diluted EPS YoY | unavailable | −33.3% | +59.1% | +31.4% | −30.4% | −6.3% | −20.0% |
| net % | -279.7% | -96.4% | -239.1% | -550.3% | -453.8% | -465.5% | -445.6% |
| Free cash flow | -2.1 m | -3.9 m | -13.1 m | -15.2 m | -13.0 m | -12.6 m | -14.6 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 8.9 m USD
- Financial debt
- 13.0 k USD
- Net debt
- -8.9 m USD
- Equity
- 9.1 m USD
- Total assets
- 13.9 m USD
- Debt / equity
- 0.00x
- Current ratio
- 2.61x
- ROE
- -188.8%
- ROA
- -113.8%
- FCF margin
- -432.4%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 3.9 m | 4.1 m | 3.1 m | 3.2 m | 3.3 m | 3.4 m | SEC (XBRL)· 17 Mar 2026verified |
| Cost of revenue | 1.4 m | 1.9 m | 1.6 m | 1.9 m | 1.8 m | 2.2 m | SEC (XBRL)· 17 Mar 2026verified |
| Gross profit | 2.4 m | 2.2 m | 1.4 m | 1.3 m | 1.5 m | 1.2 m | SEC (XBRL)· 17 Mar 2026verified |
| Research & development | 3.8 m | 5.9 m | 9.1 m | 8.3 m | 7.1 m | 7.4 m | SEC (XBRL)· 17 Mar 2026verified |
| SG&A | 120.0 k | 177.0 k | 735.0 k | — | — | — | SEC (XBRL)· 29 Mar 2023verified |
| Operating income | -4.1 m | -9.7 m | -16.7 m | -15.6 m | -15.7 m | -15.1 m | SEC (XBRL)· 17 Mar 2026verified |
| Net income | -3.7 m | -9.9 m | -17.0 m | -14.7 m | -15.3 m | -15.1 m | SEC (XBRL)· 17 Mar 2026verified |
| Diluted EPS | 0.22 | 0.35 | 0.46 | 0.32 | 0.30 | 0.24 | SEC (XBRL)· 17 Mar 2026verified |
| Weighted average diluted shares | 17.1 m | 28.5 m | 37.0 m | 45.6 m | 50.9 m | 63.6 m | SEC (XBRL)· 17 Mar 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 3.5 m | 25.6 m | 23.7 m | 10.5 m | 7.6 m | 8.9 m | SEC (XBRL)· 17 Mar 2026verified |
| Receivables | 94.0 k | 456.0 k | 78.0 k | 103.0 k | 221.0 k | — | SEC (XBRL)· 27 Mar 2025verified |
| Inventories | 1.1 m | 2.0 m | 2.9 m | 2.3 m | 2.0 m | 2.6 m | SEC (XBRL)· 17 Mar 2026verified |
| Current assets | 9.6 m | 30.3 m | 28.1 m | 14.2 m | 10.8 m | 12.6 m | SEC (XBRL)· 17 Mar 2026verified |
| Property, plant & equipment, net | 307.0 k | 713.0 k | 1.4 m | 1.5 m | 1.3 m | 993.0 k | SEC (XBRL)· 17 Mar 2026verified |
| Total assets | 10.2 m | 32.3 m | 30.2 m | 16.4 m | 12.6 m | 13.9 m | SEC (XBRL)· 17 Mar 2026verified |
| Accounts payable | 645.0 k | 881.0 k | 714.0 k | 502.0 k | — | — | SEC (XBRL)· 03 Apr 2024verified |
| Long-term debt | — | — | — | — | 161.0 k | 13.0 k | SEC (XBRL)· 17 Mar 2026verified |
| Current liabilities | 3.7 m | 4.0 m | 4.3 m | 3.9 m | 5.5 m | 4.8 m | SEC (XBRL)· 17 Mar 2026verified |
| Equity | 5.6 m | 27.0 m | 25.4 m † | 12.2 m † | 6.9 m † | 9.1 m † | SEC (XBRL)· 17 Mar 2026verified |
| Shares outstanding at year end | — | 35.8 m | 45.6 m | 45.7 m | 56.6 m | 73.1 m | SEC (XBRL)· 17 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -3.7 m | -12.6 m | -14.3 m | -12.6 m | -12.6 m | -14.6 m | SEC (XBRL)· 17 Mar 2026verified |
| Capex | 223.0 k | 533.0 k | 891.0 k | 480.0 k | 71.0 k | 36.0 k | SEC (XBRL)· 17 Mar 2026verified |
| Free cash flow | -3.9 m ≈ | -13.1 m ≈ | -15.2 m ≈ | -13.0 m ≈ | -12.6 m ≈ | -14.6 m ≈ | SEC (XBRL)· 17 Mar 2026derived |
| Investing cash flow | -4.7 m | 3.8 m | -891.0 k | -684.0 k | 446.0 k | -36.0 k | SEC (XBRL)· 17 Mar 2026verified |
| Financing cash flow | 5.9 m | 30.9 m | 13.6 m | 83.0 k | 9.2 m | 15.8 m | SEC (XBRL)· 17 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 45.8% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 57.8 m USD
Key indicators
Coverage and freshness
Score by group
46% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 3.22 – 8.44 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/E3.22 – 8.44 (Mid 5.30)12 companies used · median multiple 22.1x · quartiles 13.4x – 35.2xBDX, BSX, BVS, DXCM, GCTK, GMED, MMM, RMD, SNWV, SOLV, SYK, WST
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 45.8% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -445.6% | 9 (vs peers) | 14% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 3.1% | 26 (on a fixed band) | 18% |
| EPS CAGR 3Y · Growth | -19.5% | 0 (on a fixed band) | 18% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 2.6x | 100 (on a fixed band) | 9% |
| P/E (TTM) · Valuation | 3.3x | 92 (vs peers) | 23% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -25.3% | 0 (on a fixed band) | 18% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth13/100 · 2/2 factors with a value
- Quality· partial9/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation51/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
IceCure Medical Ltd. (ICCM). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 3.4 m USD in 2025; YoY growth 2.7%; net margin -445.6%; ROE -188.8%.
The estimated value range is 3.22–8.44 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 5.30 USD, the price of 0.79 USD leaves a potential of 570.2% (value / price − 1) and a margin of safety of 85.1% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 45.8% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 2.6x
- P/E (TTM): 3.3x
- The price is below the estimated value range
What contradicts it
- Net margin: -445.6%
- Revenue CAGR 3Y: 3.1%
- EPS CAGR 3Y: -19.5%
- FCF yield: -25.3%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Net debt / EBITDA, Interest coverage, EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Surgical & Medical Instruments & Apparatus (SIC 3841) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SYKStryker Corp | 129.3 bn | 36.2 | 16.0% | 13.8% | +11.2% | −8% / +15% |
| MMM3m Company | 100.2 bn | 28.9 | 80.8% | 14.0% | +1.5% | +13% / +134% |
| BSXBoston Scientific Corporation | 66.4 bn | 19.4 | 14.3% | 16.6% | +19.9% | −55% / −18% |
| BDXBecton, Dickinson And Company | 57.0 bn | 63.2 | 3.8% | 4.0% | +8.2% | +37% / +13% |
| RMDResMed Inc. | 33.8 bn | 21.9 | 26.4% | 27.8% | +9.9% | −6% / +52% |
| DXCMDexcom, Inc. | 33.0 bn | 34.8 | 37.7% | 19.4% | +15.6% | +39% / −23% |
| WSTWest Pharmaceutical Services, Inc. | 28.5 bn | 45.9 | 21.2% | 18.8% | +6.3% | +47% / +17% |
| SOLVSolventum Corporation | 15.2 bn | 10.9 | 34.0% | 17.3% | +0.9% | +5% / unavailable |
| GMEDGlobus Medical, Inc. | 11.7 bn | 22.3 | 11.8% | 17.0% | +16.7% | −4% / +94% |
| TFXTeleflex Incorporated | 6.4 bn | — | -28.9% | -45.8% | +17.2% | +31% / −34% |
| ICUIIcu Medical Inc | 4.3 bn | 144.2 | 1.4% | 1.4% | −6.3% | +16% / +97% |
| ATECAlphatec Holdings, Inc. | 1.3 bn | — | -1,888.0% | -10.3% | +25.0% | −63% / −30% |
| SIBNSi-Bone, Inc. | 1.1 bn | — | -7.7% | -6.2% | +20.2% | +28% / +32% |
| KIDSOrthoPediatrics Corp | 875.0 m | — | -9.8% | -12.8% | +15.4% | +81% / +9% |
| SGHTSight Sciences, Inc. | 538.0 m | — | -50.1% | -32.1% | −3.1% | +16% / +184% |
| CERSCerus Corp | 487.7 m | — | -10.7% | -2.9% | +16.1% | +37% / +50% |
| SIShoulder Innovations, Inc. | 437.4 m | — | -151.9% | -58.3% | +49.6% | +36% / unavailable |
| OFIXOrthofix Medical Inc. | 395.9 m | — | -13.9% | -7.4% | +2.9% | −40% / −12% |
| CLPTClearPoint Neuro, Inc. | 325.7 m | — | -167.5% | -79.4% | +17.8% | −30% / +76% |
| TMCITreace Medical Concepts, Inc. | 292.7 m | — | -72.0% | -29.0% | +1.6% | +51% / −49% |
| CTSOCytosorbents Corporation | 286.6 m | — | -336.2% | -48.9% | +4.1% | −72% / −81% |
| OSUROrasure Technologies, Inc | 256.6 m | — | -14.1% | -43.7% | −38.1% | +56% / −49% |
| GUTSFractyl Health, Inc. | 154.8 m | — | — | — | −100.0% | −95% / unavailable |
| KRMDKoru Medical Systems, Inc. | 151.0 m | — | -10.5% | -4.0% | +22.2% | −45% / +45% |
| LUNGPulmonx Corporation | 123.2 m | — | -90.3% | -47.9% | +8.0% | +75% / −74% |
1- and 3-year price returns: for ICCM from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 17 Mar 2026; since then the company filed 6-K (02 Nov 2026), 6-K (13 Oct 2026), 6-K (05 Oct 2026), 6-K (28 Sept 2026).
In brief
IceCure Medical Ltd. is a medical device company based in Caesarea, Israel, focused on liquid nitrogen cryoablation systems that destroy tumors through a minimally invasive procedure. The company received FDA marketing authorization in October 2025 for ProSense in low-risk breast cancer in women aged 70 and above, yet its revenue remains small at about 3.379 mn USD in fiscal 2025 while its accumulated deficit exceeds 120.4 mn USD 1.
SWOT
Strengths
- The company has a technology with FDA authorization for one clinical indication, favorable clinical data from the ICE3 study and a pioneering position in LN2 cryoablation.
- Products are authorized in many countries, and disposables generate recurring revenue with each procedure performed.
- The procedure is minimally invasive, with fast recovery and no need for reconstruction, which can attract both patients and hospitals.
Weaknesses
- Revenue is very small compared with operating losses, and the company relies on outside financing to continue operations.
- Gross margin fell in fiscal 2025 as cost of revenues rose faster than revenue.
- Dependence on distributors and insurer coverage limits the speed of commercialization.
Opportunities
- Extending FDA authorization to broader patient populations or other indications could considerably expand the addressable market.
- Obtaining CPT codes and insurance coverage could speed adoption in hospitals and clinics in the United States.
- Markets such as China, where demand grew in fiscal 2025, could become a larger revenue source if approvals expand.
Threats
- Large competitors with superior resources could limit the company's ability to gain market share.
- Difficulty raising funds on acceptable terms could force the company to scale back product development.
- Changes in regulation or additional study requirements could delay approvals or raise costs.
Risks
- Doubt about going concernhigh
Management has concluded there are conditions that raise substantial doubt about the company's ability to continue as a going concern, which could prevent it from obtaining new financing on reasonable terms.
- Minimal revenue and recurring losseshigh
The company has generated minimal revenue from product sales and has incurred losses every year since inception, and it may never become profitable.
- Reimbursement coveragemedium
If insurers do not cover the procedure, adoption in hospitals could remain slow regardless of FDA authorization.
- Post-market surveillance obligationsmedium
Meeting post-market surveillance obligations imposed by the FDA could generate additional costs and delays.
- Reliance on distributors and supplierslow
Lack of a major distribution partner could limit access to new markets, and reliance on subcontractors for manufacturing could affect quality and costs.
Investment thesis
What would need to be true (bull case)
- FDA authorization for breast cancer and support from surgical societies could turn cryoablation into a standard alternative for small, low-risk tumors.
- If CPT codes and insurance coverage are obtained, revenue from disposables could grow quickly given the recurring sales model.
- Clinical data such as the high rate of local recurrence-free patients could persuade hospitals and payers to adopt the technology.
What would break the thesis
- Revenue is minimal compared with accumulated losses, and the company could remain dependent on outside financing for a long period.
- Without CPT codes and insurance coverage, adoption could stay limited to a few clinics, which could keep revenue low.
- Competitors with much greater resources could reduce the company's chances of expanding its market share.
What to watch
- Trend in disposables revenue and gross margin versus fiscal 2025Q1 2027
- Receipt of CPT I codes for breast cancer cryoablation and results of insurer negotiations2027
- New financing or changes in liquidity relative to the going concern statementnext 10-K
- Extension of ProSense authorization or XSense approvals in new indications and countries, including China2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 17 Mar 2026; since then the company filed 6-K (02 Nov 2026), 6-K (13 Oct 2026), 6-K (05 Oct 2026), 6-K (28 Sept 2026).
The business
IceCure Medical is a commercial stage medical device company that develops and sells LN2-based cryoablation systems for treating benign and malignant tumors by freezing tissue inside the patient's body 1. Its flagship ProSense system, together with associated CryoProbes, has FDA marketing authorization for low-risk breast cancer in women aged 70 and above, and its XSense system with CryoProbes has 510(k) clearance from the FDA 1. In fiscal 2025 the company reported revenue of 3.379 mn USD and a net loss of 15.057 mn USD, and management concluded there are conditions that raise substantial doubt about its ability to continue as a going concern 1.
Segments
Systems
Sales of systems such as ProSense and IceSense3 were 1.326 mn USD in fiscal 2025, slightly below the prior year, which points to slow equipment adoption 1.
Market context
The breast cancer treatment and minimally invasive procedure market is contested, and the company argues that cryoablation could replace surgery for small, low-risk tumors, with advantages such as reducing re-excision after lumpectomy, where rates range from 14% to 20% 1. Adoption, however, depends on CPT codes, insurer coverage and distribution partnerships, and results across key markets have been uneven, with declines in India and growth in China 1.
Trends
- FDA authorization for breast cancertailwind
The FDA authorization granted in October 2025 for ProSense could open access to treatment of low-risk breast cancer, and support from breast surgeons' societies in March 2026 could help acceptance of the procedure.
- CPT codes and insurance coverageheadwind
Obtaining CPT I codes for breast cancer cryoablation and negotiating coverage with insurers are essential steps that remain unfinished, which could limit revenue growth.
- Preference for minimally invasive surgerytailwind
Physician interest in less aggressive alternatives to open surgery supports demand for cryoablation, especially for small, low-risk tumors.
- Need for additional fundingmixed
Difficulty raising capital on acceptable terms could force the company to reduce or delay development and commercialization, making capital availability a mixed factor.
Competitive position
The company operates in a tumor treatment market where large competitors have greater market share, brand recognition and financial and human resources. Competition comes mainly from thermal ablation using radiofrequency and microwave, which the company says has higher pain and complication rates, and dominant competitors could significantly limit IceCure's sales in each segment 1.
- Thermal ablation providers (radiofrequency and microwave)
The company considers heat-based technologies less advantageous because they cause more pain and complications, though they have a broader installed base 1.
- Established cancer treatment companies with dominant market shares
These companies have brand recognition, regulatory experience and greater resources, giving them dominant positions that are hard to match 1.
- Conventional breast tumor surgery
Lumpectomy remains the standard of care, and the company must show that its alternative can replace it 1.
- Other cryoablation system makers
Cryoablation rivals compete for the same hospitals and reimbursement codes, so differentiation through clinical data is essential 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)02 Nov 2026
- Current report (foreign issuer)02 Nov 2026
- Current report (foreign issuer)13 Oct 2026
- Current report (foreign issuer)05 Oct 2026
- Current report (foreign issuer)05 Oct 2026
- Current report (foreign issuer)28 Sept 2026
- Current report (foreign issuer)10 Sept 2026
- Current report (foreign issuer)24 Aug 2026
- Current report (foreign issuer)14 Aug 2026
- Current report (foreign issuer)12 Aug 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / IceCure Medical Ltd. · 17 Mar 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.